Company intelligence / Profile preview

SurVaxM program sponsor

Buffalo, New York, United States

Ownership: Private
Development stage: Other

Overview

MimiVax is a clinical-stage biotechnology company focused on the development of immunotherapeutics for cancer. Its lead candidate, SurVaxM, is a first-in-class peptide-based vaccine targeting survivin, a protein highly expressed in many cancers but absent in normal adult tissues. The company is currently evaluating SurVaxM in clinical trials for glioblastoma, multiple myeloma, and other survivin-expressing tumors. MimiVax was spun out of the Roswell Park Comprehensive Cancer Center to commercialize this novel immunotherapy platform.

Therapeutic areas: Oncology
Modalities: VaccinePeptides
Industry: Biotech

Partnerships

Roswell Park Comprehensive Cancer Center

Beyond the preview

Go deeper on SurVaxM program sponsor.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SurVaxM program sponsor.

Explore the full profile